86572 Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices 

I. General Description of the 

Committee’s Duties 

The committee provides advice and 

consultation to the Commissioner of 

Food and Drugs (the Commissioner) on 

the technical feasibility, reasonableness, 

and practicability of performance 

standards for electronic products to 

control the emission of radiation from 

such products, and may recommend 

electronic product radiation safety 

standards to the Commissioner for 

consideration. 

II. Criteria for Voting Members 

The committee consists of a core of 15 

voting members including the Chair. 

Members and the Chair are selected by 

the Commissioner or designee from 

among authorities knowledgeable in the 

fields of science or engineering, 

applicable to electronic product 

radiation safety. Members will be 

invited to serve for overlapping terms of 

up to 4 years. Terms of more than 2 

years are contingent upon the renewal 

of the committee by appropriate action 

prior to its expiration. 

III. Nomination Procedures 

Any interested person may nominate 

one or more qualified individuals for 

membership on the committee. Selfnominations are also accepted. 

Nominations must include a current, 

complete re ́sume ́ or curriculum vitae for 

each nominee, including current 

business address and/or home address, 

telephone number, and email address if 

available and a signed copy of the 

Acknowledgement and Consent form 

available at the FDA Advisory 

Nomination Portal (see ADDRESSES). 

Nominations must also specify the 

advisory committee for which the 

nominee is recommended. Nominations 

must also acknowledge that the 

nominee is aware of the nomination 

unless self-nominated. FDA will ask 

potential candidates to provide detailed 

information concerning such matters 

related to financial holdings, 

employment, and research grants and/or 

contracts to permit evaluation of 

possible sources of conflicts of interest. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: December 22, 2020. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2020–28833 Filed 12–29–20; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; SBIR Contract Review Topic 

20. 

Date: January 12, 2021. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rahat (Rani) Khan, Ph.D. 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078 Bethesda, MD 20892, 301–594–7319 

khanr2@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: December 22, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28842 Filed 12–29–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Health, Behavior, and Context 

Subcommittee. 

Date: February 22, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NICHD/NIH, 6710B Rockledge 

Drive, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kimberly L. Houston, 

M.D., Scientific Review Officer, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6701B 

Rockledge Drive, Room 2137C, Bethesda, MD 

20892, 301–827–4902, kimberly.houston@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: December 23, 2020. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28841 Filed 12–29–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices 86573 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Sponsor 

and Regulatory Oversight Support TEP. 

Date: January 26, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W102, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shakeel Ahmad, Ph.D., 

Chief Research Technology and Contract 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W102, 

Rockville, Maryland 20850, 240–276–6442, 

ahmads@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Program Project (P01) Review III. 

Date: February 17–18, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W240, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Rockville, 

Maryland 20850, 240–276–5122, 

hasan.siddiqui@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–8: 

Research Answers to NCI Provocative 

Questions. 

Date: February 25, 2021. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W248, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shree Ram Singh, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W248, Rockville, 

Maryland 20850, 240–672–6175, singhshr@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Research to 

Reduce Morbidity and Improve Care for 

Pediatric and AYA Cancer Survivors (R01/ 

R21). 

Date: March 4–5, 2021. 

Time: 11:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W606, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Timothy C. Meeker, M.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W606, Rockville, 

Maryland 20850, 240–276–6464, meekert@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Aging, 

Cancer Initiating Cells, and Cancer 

Progression (U01). 

Date: March 18, 2021. 

Time: 12:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove 9609 Medical Center Drive, Room 

7W606, Rockville, Maryland 20850 

(Telephone Conference Call) 

Contact Person: Timothy C. Meeker, M.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W606, Rockville, 

Maryland 20850, 240–276–6464, meekert@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: December 23, 2020. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28840 Filed 12–29–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Quarterly IRS Interest Rates Used in 

Calculating Interest on Overdue 

Accounts and Refunds on Customs 

Duties 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This notice advises the public 

that the quarterly Internal Revenue 

Service interest rates used to calculate 

interest on overdue accounts 

(underpayments) and refunds 

(overpayments) of customs duties will 

remain the same from the previous 

quarter. For the calendar quarter 

beginning January 1, 2021, the interest 

rates for overpayments will be 2 percent 

for corporations and 3 percent for noncorporations, and the interest rate for 

underpayments will be 3 percent for 

both corporations and non-corporations. 

This notice is published for the 

convenience of the importing public 

and U.S. Customs and Border Protection 

personnel. 

DATES: The rates announced in this 

notice are applicable as of January 1, 

2021. 

FOR FURTHER INFORMATION CONTACT: 

Bruce Ingalls, Revenue Division, 

Collection Refunds & Analysis Branch, 

6650 Telecom Drive, Suite #100, 

Indianapolis, Indiana 46278; telephone 

(317) 298–1107. 

SUPPLEMENTARY INFORMATION: 

Background 

Pursuant to 19 U.S.C. 1505 and 

Treasury Decision 85–93, published in 

the Federal Register on May 29, 1985 

(50 FR 21832), the interest rate paid on 

applicable overpayments or 

underpayments of customs duties must 

be in accordance with the Internal 

Revenue Code rate established under 26 

U.S.C. 6621 and 6622. Section 6621 

provides different interest rates 

applicable to overpayments: One for 

corporations and one for noncorporations. 

The interest rates are based on the 

Federal short-term rate and determined 

by the Internal Revenue Service (IRS) on 

behalf of the Secretary of the Treasury 

on a quarterly basis. The rates effective 

for a quarter are determined during the 

first-month period of the previous 

quarter. 

In Revenue Ruling 2020–28, the IRS 

determined the rates of interest for the 

calendar quarter beginning January 1, 

2021, and ending on March 31, 2021. 

The interest rate paid to the Treasury for 

underpayments will be the Federal 

short-term rate (0%) plus three 

percentage points (3%) for a total of 

three percent (3%) for both corporations 

and non-corporations. For corporate 

overpayments, the rate is the Federal 

short-term rate (0%) plus two 

percentage points (2%) for a total of two 

percent (2%). For overpayments made 

by non-corporations, the rate is the 

Federal short-term rate (0%) plus three 

percentage points (3%) for a total of 

three percent (3%). These interest rates 

used to calculate interest on overdue 

accounts (underpayments) and refunds 

(overpayments) of customs duties